The CIMON study results show that MaaT033 is safe, well tolerated and effective for gut microbiota restoration in AML patients receiving IC and ATB. A Phase II trial is planned to evaluate MaaT033 in preventing alloHCT complications.
For IC, 20 patients received cytarabine associated with an anthracycline, 1 patient received azacytidine. Conclusion The CIMON study results show that MaaT033 is safe, well tolerated and effective for gut microbiota restoration in AML patients receiving IC and ATB. A Phase II/III trial is planned to evaluate MaaT033 in preventing allo-HSCT complications.